Fluorine-hydrogen performance evaluation. Phase I, part I - Analysis, design, and demonstration of high performance injectors for the liquid fluorine-gaseous hydrogen combination Final report

Analysis, design, and demonstration of high performance injectors for liquid fluorine- gaseous hydrogen propellant combinatio

The Lindelöf number greater than continuum is u-invariant

2000 Mathematics Subject Classification: 54C35, 54D20, 54C60.Two Tychonoff spaces X and Y are said to be l-equivalent (u-equivalent) if Cp(X) and Cp(Y) are linearly (uniformly) homeomorphic. N. V. Velichko proved that countable Lindelöf number is preserved by the relation of l-equivalence. A. Bouziad strengthened this result and proved that any Lindelöf number is preserved by the relation of l-equivalence. In this paper it has been proved that the Lindelöf number greater than continuum is preserved by the relation of u-equivalence

Effect of Global Warming Scenarios on Carotenoid Pigments Gracilaria changii

The phenomenon of global warming is an increase in the earth's temperature due to the greenhouse effect where 50% of the main contributors to the greenhouse effect are carbon dioxide (CO2). Carbon dioxide is one of the ingredients needed for photosynthesis. Photosynthesis is carried out by plants that have chloroplasts. Plants in the waters are Seaweed. Gracilaria changii is a type of red seaweed (Rhodophyceae). The dominant pigment from Gracilaria changii is carotenoids. Carotenoid serves as a light energy absorbent for photosynthesis and serves to protect chlorophyll from light damage. Seeing the important role of carotenoids in Gracilaria changii so that this study aims to determine the effect of increasing temperature and carbon dioxide on carotenoid pigments. Research on the scenario of global warming in this region was first carried out on a laboratory scale, many previous studies were carried out in the cultivation area. This study was conducted for 40 days, seaweed that has been cleaned is put into an aquarium and given an injection of CO2. We were exposed to present-day control seawater (400 ppm pCO2 ) and seawater treated with CO2 to simulate ocean conditions predicted for the next 50–100 years (700 ppm, 1000 ppm, and 1300 ppm) and temperature treatment (30 oC, 32 oC, 34 oC). The research design applied in this study is a Completely Randomized Design consisting of nine treatments with three replications. Data analysis used is Analysis of Variance (ANOVA) continued by Post hoc Test. The results obtained from this study there were significant differences (

The honeymoon is over

I wore a diaper on the airplane ride home from my honeymoon. Yup. You read that right. An adult diaper on the 8-hour, trans-Atlantic flight from Rome to Minneapolis with a Christmas day stop in Chicago. I was in seat 5B snuggled in between my newly minted husband and my dad. This, my friends, is what romantic dreams are made of

The Lindelöf number is fu-invariant

Two Tychonoff spaces X and Y are said to be l-equivalent (u-equivalent) if Cp(X) and Cp(Y) are linearly (uniformly) homeomorphic. N.V.Velichko proved that the Lindelцf property is preserved by the relation of l-equivalence. A. Bouziad strengthened this result and proved that the Lindelцf number is preserved by the relation of l-equivalence. In this paper the concept of the support different variants of which can be founded in the papers of S.P. Gul'ko and O.G. Okunev is introduced. Using this concept we introduce an equivalence relation on the class of topological spaces. Two Tychonoff spaces X and Y are said to be fu-equivalent if there exists an uniform homeomorphism h: Cp(Y) → Cp(X) such that suppx and suppx are finite sets for all x∈X and y∈Y. This is an intermediate relation between relations of u- and l-equivalence. In this paper it has been proved that the Lindelцf number is preserved by the relation of fu-equivalence

First in Man Studies of Pharmacokinetic Profiles of a Novel Oral PTH(1-34)

Background: PTH(1-34) (Teriparatide) is an anabolic agent used in treatment of osteoporosis. It promotes bone formation and reduces the risk of vertebral and some non-vertebral fractures. The route of administration by daily subcutaneous (sc) injection can cause problems in certain patients. A new oral delivery system for human PTH(1-34) has been developed as a possible treatment option. Galitzer et al. presented pre-clinical data (ASBMR 2012, MO0402) and first-in-human results (ASBMR 2013, FR0378) on safety, tolerability and absorption dynamics of oral PTH(1-34) in various dosages. We now describe the pharmacokinetics (PK) of oral PTH(1-34) compared to sc and placebo in healthy subjects. Objective: A single-center, double blinded, triple crossover study was designed to compare the 1.8 mg optimal dose of oral PTH(1-34) against standard dosage of teriparatide injection and oral placebo. Method: The study was conducted following and in accordance with the Hadassah Medical Center ethical approval committee. 12 healthy volunteers (6m/6f), 18-50y, received three treatments: single sc injection of 20µg FORTEO®, 1.8 mg oral PTH(1-34), or placebo. Blood samples were collected at time 0, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180, 240, 300 minute post dose. Plasma concentration of PTH(1-34) (IDS, Tyne and Wear, UK) and cyclic adenosine 3’,5’monophosphate (cAMP) were measured on all samples. Results: All 12 subjects on oral PTH(1-34) showed rapid, post dose increase then decrease of PTH(1-34), from baseline mean (±SD) of 5.9 (1.8) pg/mL to peak mean of 185.3 (±128.8) pg/mL. PK profiles of oral PTH(1-34) showed Cmax (pg/mL), Tmax (mins), AUC0-last of 238.3 (110.8), 17.5 (5.4) and 6161.7 (2726.7), respectively; whereas sc showed mean Cmax (pg/mL), Tmax (mins), AUC0-last of 172.3 (55.7), 20.8 (8.7) and 13965.9 (2984.8), respectively. Plasma cAMP increased in all subjects in response to oral PTH(1-34) and sc treatment. Serum adjusted calcium in all subjects remained within normal limits throughout the studies. Conclusion: PK profiles showed a single oral dose of 1.8 mg PTH(1-34) is rapidly absorbed, and no significant difference in Cmax and Tmax when compared with 20µg of sc teriparatide. A significant difference in the rate of plasma clearance and AUC0-last value was observed (fig.1). These differing profiles and modality of administration of PTH(1-34) could offer unique advantages in the treatment of calcium and metabolic bone disorders